RNS Number : 3118Z
Theracryf PLC
04 March 2025
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Director/PDMR Shareholding
Alderley Park, UK - 4 March 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry has been notified that Dr Helen Kuhlman, Chief Business Officer has purchased 1,500,000 Ordinary Shares of 0.25 pence each ("Ordinary Shares") at a price of 0.24 pence per Ordinary Share.
The notifiable interest of Dr Helen Kuhlman is now 2,555,744 Ordinary Shares, representing 0.5% of the issued Ordinary Share capital of the Company.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Dr Helen Kuhlman
2
Reason for notification
a.
Position/Status
Chief Business Officer (PDMR)
b.
Initial notification/ Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
TheraCryf plc
b.
LEI
213800NO3E6TSTQO8K20
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary Shares of 0.25p each GB00BSVYN304
b.
Nature of the transaction
Purchase of Ordinary Shares
c.
Price(s) and volume(s)
Price(s)
Volume(s)
0.24 pence
1,500,000
d.
Aggregated information - Aggregated Volume - Price
As above
e.
Date of the transaction
4 March 2025
f.
Place of the transaction
XLON
Enquiries
TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, CBO
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker
+44 (0)20 3657 0050
Vigo Consulting Rozi Morris
+44 (0)20 7390 0231theracryf@vigoconsulting.com
About TheraCryf plc
TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).
TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.
For further information, please visit: www.theracryf.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAFDLESPSEFA
